Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.
Emma J KooistraNicole J B WaaldersInge GrondmanNico A F JanssenAline H de NooijerMihai M NeteaFrank L van de VeerdonkEsther EwaldsJohannes G van der HoevenMatthijs KoxPeter Pickkersnull nullPublished in: Critical care (London, England) (2020)
Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.
Keyphrases